On this page

Dose Insider / Analyses / Wegovy vs Zepbound

Wegovy vs Zepbound: What the Head-to-Head Actually Showed

Updated November 19, 2026 · 21 min read · SURMOUNT-5, trial registry, FDA labels

One randomized trial has put Wegovy and Zepbound against each other. After 72 weeks, people on Zepbound (tirzepatide) had lost 20.2% of their body weight and people on Wegovy (semaglutide) 13.7%. At the trial's average starting weight of 249 lb, that is 50 lb against 33 lb.

The trial is called SURMOUNT-5. It enrolled 751 adults with obesity and without diabetes at 32 sites in the United States and Puerto Rico, and the results appeared in the New England Journal of Medicine in May 2025.1 Eli Lilly, which makes Zepbound, paid for it.

The headline holds up. It leaves out how many people lost far less than the average, how the side effects split between the drugs and what the extra pounds cost. It also predates a stronger Wegovy that the trial never tested. Each section below takes one of those questions, and the calculators run on the trial's own numbers with your weight and your prices.

How much would each drug take off my weight?

The trial reports weight loss as a percentage, so the answer in pounds depends on where you start. Enter your weight. The two large numbers are the trial averages applied to you. The dots show what an average hides: how many people out of 100 reached the goal you pick.

Your numbers from the trialSURMOUNT-5 · week 72
Unit
Zepbound · 20.2%—
Wegovy · 13.7%—
Goal: lose at least
Count

Trial averages and published shares, not a forecast for one person. The paper gives no 30% figure for everyone who started, so that goal uses finishers only.

Log each dose and each weigh-in, and see your own curve week by week.

Track it in Dose Insider

An average of 20.2% does not mean everyone lost 20.2%. On Zepbound about 1 person in 5 (18.4%) finished with less than 10% off. On Wegovy it was 2 in 5 (39.5%).3 At the other end, 31.6% of the Zepbound group and 16.1% of the Wegovy group lost a quarter of their body weight or more.

Louis Aronne of Weill Cornell Medicine, who led the trial, said when the results came out that “we still have people who don't respond to them.”11

Cheat sheetThe head-to-head in numbers
Dose Insider · SURMOUNT-5, 72 weeks
Zepbound · tirzepatideWegovy · semaglutide
Dose in the trial15 mg, or 10 mg if 15 was not tolerated2.4 mg, or 1.7 mg if 2.4 was not tolerated
Average weight loss20.2% · 22.8 kg · 50.3 lb13.7% · 15.0 kg · 33.1 lb
Waist18.4 cm (7.2 in) smaller13.0 cm (5.1 in) smaller
Lost 15% or more64.6%40.1%
Lost 25% or more31.6%16.1%
Lost less than 10%18.4%39.5%
Nausea43.6%44.4%
Vomiting15.0%21.3%
Injection-site reaction8.6%0.3%
Stopped the drug over side effects6.1%8.0%
Self-pay price, full dose$449 a month$349 a month
On the label besides weightObstructive sleep apneaHeart attack and stroke risk, MASH, ages 12 and up, a pill form
Dose Insider · /science/wegovy-vs-zepbound-head-to-head

What exactly did SURMOUNT-5 test?

SURMOUNT-5 enrolled adults with a BMI of 30 or more, or of 27 or more together with high blood pressure, abnormal cholesterol, sleep apnea or cardiovascular disease. Everyone had tried to lose weight by diet at least once without success. People with diabetes were excluded.2

The average participant was 44.7 years old, weighed 113.0 kg (249 lb), had a BMI of 39.4 and had lived with obesity for 15.6 years.5 Women made up 65% of the group, 19% of participants were Black and 26% Hispanic or Latino.2 More than half, 425 people, had prediabetes at the start.6

Half were assigned by chance to tirzepatide and half to semaglutide, one injection a week for 72 weeks, alongside advice on diet and exercise. Doses went up every 4 weeks. The target was the top dose, 15 mg of tirzepatide or 2.4 mg of semaglutide, and people who could not tolerate it stayed one step lower, at 10 mg or 1.7 mg. The paper calls this the maximum tolerated dose.1

Two features of the design shape how to read the result. The trial was open-label, which means participants and doctors knew who was getting which drug. And it had no placebo group, so it measures the distance between the two drugs and not the effect of either one against nothing.

What did the scale show at week 72?

The Zepbound group lost 20.2% of body weight (95% confidence interval 19.1 to 21.4) and the Wegovy group 13.7% (12.6 to 14.9). The difference was 6.5 percentage points, with an interval of 4.9 to 8.1, so chance is not a serious explanation.1,2

In absolute terms the averages were 22.8 kg (50.3 lb) and 15.0 kg (33.1 lb).3,4 As a ratio, Zepbound took off 47% more weight than Wegovy.

Waist size followed. It shrank by 18.4 cm (7.2 in) with Zepbound and 13.0 cm (5.1 in) with Wegovy, and BMI fell by 8.5 and 6.0 points.2

These figures count everyone who was randomized, including people who quit the drug partway. The registry also reports what the result would look like if everyone had stayed on treatment and reached the top dose: 21.8% against 15.4%.2 The distance between the drugs barely moves, 6.4 points in place of 6.5. People dropping out is not what created the gap.

Why do two sets of odds circulate for the same trial?

You may have read that 82% of Zepbound users lost at least 10% of their weight, and elsewhere that 88% did. Both numbers are real. They answer different questions.

The journal paper counts all 751 people who were randomized. Someone who stopped the drug in month three stays in the count, and a statistical model fills in the weights that were never measured.1,3 The trial registry reports observed values instead: the 318 people in each group who stepped on the scale at week 72.2 People who finish a trial are more often the ones the drug suits, so their numbers look better.

Everyone who startedFinished 72 weeks
Lost at leastZepboundWegovyZepboundWegovy
10%81.6%60.5%87.7%66.7%
15%64.6%40.1%71.7%45.0%
20%48.4%27.3%55.0%31.1%
25%31.6%16.1%36.5%18.6%
30%not reportednot reported23.0%8.2%

The first pair fits someone deciding whether to start, who cannot know yet whether they will stay the course. The second fits someone already months in and tolerating the drug.

In both versions the gap is widest in the middle of the range. For a 20% loss the difference is 21 points among everyone who started. That works out to one extra person reaching 20% for every five who take Zepbound in place of Wegovy.

How early does the gap show?

By week 24. In a later analysis of the trial, 44% of the Zepbound group and 21% of the Wegovy group had already lost 15% or more by then.7 The authors call these people rapid responders. On both drugs they went on to reach every weight-loss threshold more often than slower responders. They also reported more stomach, gut and gallbladder problems, yet they were no more likely to quit treatment.

Zepbound takes that early lead despite a longer ramp. Both labels raise the dose every 4 weeks to limit nausea, but Wegovy has four steps below its full dose and Zepbound five.22,23 Slide through the weeks to see where each schedule stands.

Dose by weekFDA label schedules
Zepbound—
Wegovy—

The schedule if every step is taken on time. Both labels allow a step to be delayed when a dose is hard to tolerate, and the Zepbound label accepts 5 mg or 10 mg as a long-term dose.

Outside a trial, people climb the steps more slowly. In US health records for 2,396 adults who started one of the two drugs between December 2023 and June 2024 and kept taking it, weight was down 11.2% with tirzepatide and 8.8% with semaglutide after 6 months.8 Only 42% of the tirzepatide group had reached 10 mg or more by then, while 68% of the semaglutide group were on 1.7 mg or more. Tirzepatide was ahead on a lower rung of its ladder.

Which one is harder on the stomach?

Neither, by much. Nausea hit 44% of people on each drug, and constipation and diarrhea were level too. The differences were in vomiting and acid reflux, which were more common on Wegovy, and in skin reactions where the needle goes in, which were almost exclusive to Zepbound.2

Side effects, drug by drugRegistry · 374 and 376 people
Show
Order by
ZepboundWegovy

Tap a row for the head count. The registry lists every event reported by at least 5% of either group over 72 weeks, whatever its cause, which is why colds and Covid-19 are on the full list.

Most of these events were mild or moderate and came in the weeks when the dose was going up.1

How many people gave up because of side effects? Here again three different figures circulate, and all three are right. 6.1% of the Zepbound group and 8.0% of the Wegovy group stopped taking the drug because of an adverse event.3 Counting stomach and gut problems alone, it was 2.7% and 5.6%.4 And 6 people in each group left the study altogether for that reason.2 Stopping the drug and leaving the study are separate events, because a person can stop the injections and still come in to be weighed.

Serious adverse events were recorded in 18 of 374 people on Zepbound (4.8%) and 13 of 376 on Wegovy (3.5%). Nobody died. Gallstones serious enough to be listed occurred in 2 people on Zepbound and 3 on Wegovy, and 2 more people on Wegovy had a stone in the bile duct.2 With counts this small the trial cannot say which drug causes fewer rare events.

Two smaller differences went in Wegovy's favor. Hair loss was reported by 8.3% of people on Zepbound and 6.1% on Wegovy. Injection-site reactions were reported by 32 people on Zepbound and 1 on Wegovy; the Zepbound label lists them among its common adverse reactions.23

Did anything besides weight differ?

Follow-up analyses of the same 750 people have appeared since, most of them with the trial's own investigators among the authors. They add detail to the weight result.

Blood sugar

Among the 425 people who started with prediabetes, 89.9% on Zepbound and 76.2% on Wegovy had normal blood sugar at week 72. Normal here means an HbA1c below 5.7% together with a fasting glucose below 100 mg/dL. HbA1c fell by 0.60 points with Zepbound and 0.48 with Wegovy.6

Predicted heart risk

A risk equation built from the Framingham Heart Study put the participants' average 10-year risk of cardiovascular disease at 9.3% before treatment. By week 72 the estimate had dropped by 2.4 points with Zepbound and 1.4 with Wegovy.9 This is a prediction from BMI and blood pressure. It is not a count of heart attacks, and the trial was too small and too short to count those.

How people felt

On the SF-36 health questionnaire both groups rated their physical health higher at week 72 than at the start, and the mental-health summary score did not change significantly in either group. Zepbound was ahead on one domain, general health (5.45 points against 4.20). On both drugs, the people who lost the most weight reported the largest gains in physical function and the largest drop in bodily pain.5

Treatment targets

Obesity specialists have proposed goals for treatment that go beyond a percentage: a waist-to-height ratio under 0.53, a BMI under 27, or both. Between 23% and 34% of the Zepbound group reached them, depending on the goal, against 14% to 21% of the Wegovy group.10

Men and women

Men lost about 6 percentage points less than women on both drugs.4 Men made up 35% of the trial (265 of 750), a larger share than in most obesity trials, and the authors suggest that is why both averages came out slightly below earlier studies of the same drugs.

Why would Zepbound take off more?

The two drugs are built differently. Semaglutide imitates one gut hormone, GLP-1, which regulates appetite and slows the emptying of the stomach.22 Tirzepatide acts on the GLP-1 receptor and also on the receptor for a second hormone, GIP; its label describes it as a GIP receptor and GLP-1 receptor agonist.23 The trial's lead investigator attributes the extra weight loss to that double action, while adding that the pathways involved are far from understood.11

They also behave differently over the week. Tirzepatide has a half-life of about 5 days and semaglutide about 7, so by the day before the next shot more of the tirzepatide dose has faded. We cover that in why the day before your shot feels different. The shorter half-life did not stop tirzepatide from coming out ahead.

What should make me cautious about this trial?

Eli Lilly paid for SURMOUNT-5, and a Lilly employee helped prepare the manuscript, as the paper's acknowledgments state.1 Louis Aronne, the lead investigator, is a paid consultant to Lilly and sits on a paid advisory board for Novo Nordisk, according to his university.11 Sponsorship does not make a result wrong. Semaglutide performed in this trial close to how it performed in Novo Nordisk's own, as the next section shows. But the sponsor chose the question, and the question was weight.

The trial was open-label. Someone who knows they drew the drug they hoped for may work harder at the diet, and someone disappointed may drift away. On the second point the data are reassuring: the same number finished in each group, 319.2

It ran for 72 weeks. Both drugs are meant to be taken for years, and the trial says nothing about year three.

It excluded people with diabetes, so the percentages do not transfer to them, and it took place only in the United States and Puerto Rico. Also kept out were people with a history of pancreatitis, with medullary thyroid cancer in the family, or with unstable major depression in the previous two years.2 Both labels carry a boxed warning about thyroid C-cell tumors and a warning about pancreatitis, and the trial adds nothing on safety for those groups.22,23

It measured weight and waist. It did not measure heart attacks, strokes or deaths, where so far only one of the two drugs has a completed trial in people with obesity.

And it tested Wegovy at 2.4 mg, which was the highest dose at the time. In March 2026 the FDA approved one three times as large.

Does the 7.2 mg Wegovy close the gap?

Partly, as far as separate trials can tell. Wegovy HD is a 7.2 mg weekly dose that the FDA approved on March 19, 2026 for adults who have taken 2.4 mg for at least 4 weeks and need more weight loss.13

Its trial, STEP UP, gave 1,407 adults without diabetes semaglutide 7.2 mg, 2.4 mg or placebo for 72 weeks. Weight fell by 18.7% on 7.2 mg and 15.6% on 2.4 mg.12 The higher dose brought a side effect that 2.4 mg rarely causes: altered skin sensation, such as tingling or skin that is sore to the touch, in 22% of people against 6%.13

Fig. 1 · Six trial arms, four trialsAll randomized
Average weight loss at 72 weeks (68 weeks in STEP 1), counting everyone randomized. Only the two SURMOUNT-5 arms were compared directly. The same 2.4 mg dose of Wegovy scored between 13.7% and 15.6% depending on the trial.

Set 18.7% beside Zepbound's 20.2% and the gap shrinks from 6.5 points to 1.5. But that comparison crosses two trials with different participants, and Fig. 1 shows how far a single dose can move from one trial to the next. The 2.4 mg dose of semaglutide scored 13.7% in Lilly's trial, 14.9% in STEP 1 and 15.6% in STEP UP. Tirzepatide 15 mg scored 20.9% in its own first trial, SURMOUNT-1.1,12,14,15 Part of the reason is who was enrolled. Men lose less, and SURMOUNT-5 had 35% men against 26% in STEP UP.

SURMOUNT-5 did not include the 7.2 mg dose, so the head-to-head evidence stops at 2.4 mg. For someone already on Wegovy 2.4 mg with a modest result, the choice is now between two untested-against-each-other moves: go up to 7.2 mg, or switch to Zepbound.

What does each drug do besides weight loss?

Weight is one outcome. For some people the deciding fact sits on the label, in what the FDA has accepted each drug does for the heart, the liver or sleep. Pick what applies to you and the table narrows to those rows.

What applies to you?FDA labels · trials

Past heart attack or stroke
WegovyOn the label
Lowers the risk of cardiovascular death, heart attack and stroke in adults with heart disease and obesity or overweight. In SELECT, 6.5% had such an event on semaglutide and 8.0% on placebo.16
ZepboundNot on the label
The outcomes trial, SURMOUNT-MMO, has 15,374 participants and no posted results.21
Obstructive sleep apnea
WegovyNot on the label
No sleep apnea indication.22
ZepboundOn the label
For moderate to severe sleep apnea in adults with obesity. Breathing pauses fell by 25.3 an hour against 5.3 on placebo, from about 50.17
Fatty liver disease with scarring (MASH, stages F2 to F3)
WegovyOn the label
Accelerated approval. In ESSENCE the liver inflammation resolved in 62.9% on semaglutide and 34.3% on placebo.18
ZepboundNot on the label
No MASH indication.23
Heart failure with preserved ejection fraction
WegovyNot on the label
Heart failure is not among its listed uses.22
ZepboundTrial, not on the label
In SUMMIT, 9.9% died of cardiovascular causes or had worsening heart failure on tirzepatide and 15.3% on placebo, among 731 people over about two years.19
Prediabetes
WegovyTrial, not on the label
76.2% back to normal blood sugar at week 72 in SURMOUNT-5.6
ZepboundTrial, not on the label
89.9% back to normal blood sugar at week 72 in SURMOUNT-5.6
Age 12 to 17
WegovyOn the label
The injection is approved for weight reduction from age 12.22
ZepboundNot on the label
Adults only.23
A pill in place of an injection
WegovyOn the label
A daily tablet, 25 mg at full dose. The label lets people on the 2.4 mg injection move to it a week after their last shot.22
ZepboundInjection only
Pens and vials. Lilly's weight-loss pill, Foundayo, is a different drug, orforglipron.27
Birth control pills
WegovyNo instruction
The label has no warning about oral contraceptives.22
ZepboundLabel instruction
Switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.23

The largest hole in the evidence is on Zepbound's side of that table. Wegovy has SELECT, a trial of 17,604 people with heart disease in which semaglutide cut heart attacks, strokes and cardiovascular deaths from 8.0% to 6.5% over a little more than three years.16 The matching trial of tirzepatide in obesity is still running.21 Until it reports, a person whose main worry is a second heart attack has proof for one drug and a forecast for the other.

If you have type 2 diabetes

SURMOUNT-5 does not cover you, but other studies do. In SURPASS-CVOT, 13,165 people with type 2 diabetes and heart disease took tirzepatide or dulaglutide, an older GLP-1 drug. A cardiovascular event occurred in 12.2% on tirzepatide and 13.1% on dulaglutide, which passed the test for “not worse” and missed the test for “better”.20 On that basis the FDA added heart protection to the label of Mounjaro, the diabetes brand of tirzepatide, in 2026.26 Zepbound's label has no such line.

For weight, a study of US health records matched 18,386 adults starting one drug or the other, half of them with type 2 diabetes. After 12 months on treatment the tirzepatide group had lost 6.9 percentage points more, and stomach and gut side effects were equally common. More than half of each group had stopped the drug within the year.32

What does the extra weight loss cost?

For people paying cash, both makers now sell direct. Wegovy pens cost $349 a month at every dose up to 2.4 mg, with the first two fills at $199 for new patients until December 31, 2026. Wegovy HD costs $399.24 Zepbound in a KwikPen or vials costs $299 a month at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up, provided each refill is bought within 45 days of the last. Miss that window and 10 mg and above cost $699.25

At full dose, then, Zepbound costs $100 a month more. Per pound lost, the order reverses.

Cost of 72 weeks, and per poundPrices read Nov 19, 2026
Wegovy's new-patient price, $199 for the first two fills
Zepbound—
Wegovy—

18 four-week fills, doses rising on the label schedule, trial-average weight loss. Zepbound prices assume every refill lands inside the 45-day window. Doctor visits are not included.

Keep doses, refills and weight in one log, so you can see what each month bought.

Track it in Dose Insider

Over the trial's 72 weeks, which is 18 four-week fills, the listed prices add up to $7,882 for Zepbound and $5,982 for Wegovy. Divide by the average weight lost and a 250 lb person pays about $156 for each pound on Zepbound and $175 on Wegovy. The monthly bill is higher and the price of the result is lower.

The sum stops at week 72 and the treatment does not. A further year of 13 fills costs $5,837 for Zepbound at $449 and $4,537 for Wegovy at $349, and by then most of the weight loss is behind you. The cheaper drug per pound in the first 72 weeks is the dearer one to stay on.

With insurance, the plan's drug list often decides before the trial data get a say. The pharmacy benefit manager CVS Caremark removed Zepbound from its standard list in 2025 in favor of Wegovy, then restored it as a second preferred drug on October 1, 2026.27 Medicare has paid for both for weight loss since July 1, 2026 under a temporary program, the Medicare GLP-1 Bridge, at $50 a month for people who meet its criteria. The program runs until December 31, 2027 and takes Zepbound only in the KwikPen.28

Can I switch from one to the other?

People switch in both directions, most often because their plan changed its drug list, their weight stopped moving or the stomach side effects never settled.

Neither label gives a conversion between Wegovy doses and Zepbound doses. The Zepbound label has one way in, 2.5 mg a week for 4 weeks, and says the drug should not be combined with any GLP-1 medicine.23 The Wegovy label starts everyone at 0.25 mg.22 Whether to restart at the bottom after months on the other drug is the prescriber's call. SURMOUNT-5 offers nothing on it, because nobody in the trial switched.

The best evidence on what happens afterwards was presented at ObesityWeek in November 2026. Researchers at Cleveland Clinic followed 20,486 adults with obesity or type 2 diabetes who used either drug between 2021 and 2025.29 After 2 years, people who stayed on their first drug had lost 10.9% of their weight, people who switched between the two had lost 16%, and people who stopped had lost 3.9%.

The direction of the switch mattered. Moving from semaglutide to tirzepatide brought about 3 kg more weight loss than staying on semaglutide. Moving the other way cost about 4.5 kg compared with staying on tirzepatide. These are health records and not a randomized trial, and people who switch differ from people who do not. Still, the result points the same way as SURMOUNT-5.

What happens after week 72?

SURMOUNT-5 ended with everyone still on a drug. What comes next is known from other trials and is the same for both: most of the weight returns when the injections stop.

In the extension of Novo Nordisk's STEP 1 trial, people who had lost 17.3% on semaglutide regained 11.6 points of it within a year of stopping, two-thirds of the loss.30 In Lilly's SURMOUNT-4, people who had lost 20.9% in 36 weeks on tirzepatide were moved to placebo and regained 14.0% of their weight over the following year, while those who stayed on the drug lost another 5.5%.31

So the choice between the two is a choice of what to take for years. The Cleveland Clinic records make the same point from the other side: the people who stopped were down 3.9% at two years, less than every group that stayed on some treatment.29 We look at who stops, and why, in why people stop GLP-1s.

So which one is better?

For weight alone, Zepbound. At the doses the trial tested there is little room for doubt: more weight off on average, twice the share of people losing a quarter of their weight, and no more nausea.

The reasons to choose Wegovy lie outside the trial. It has proof of fewer heart attacks and strokes in people with heart disease. It is approved for fatty liver disease with scarring and from age 12. It comes as a pill, costs $100 a month less at the pharmacy counter, and now has a 7.2 mg dose that narrows the distance. And for many people the question is settled by which of the two their plan pays for.

Is Zepbound the same drug as Mounjaro?

Yes. Both are tirzepatide from Eli Lilly. Mounjaro is the brand approved for type 2 diabetes and Zepbound the brand approved for weight loss and sleep apnea.23,26

Can I take Wegovy and Zepbound together?

The Zepbound label says it should not be used together with any GLP-1 medicine, and Wegovy is one.23

I lost less than 10% on Wegovy. Would Zepbound work for me?

The trial cannot answer for one person, because nobody in it tried both drugs. It does show that losing less than 10% was half as common on Zepbound (18.4% against 39.5%), and the Cleveland Clinic records show an extra 3 kg on average after a switch from semaglutide.3,29

How the calculators work

The weight calculator multiplies your weight by the trial's average losses, 20.2% and 13.7%. The dots are the published shares of people who reached each threshold, rounded to whole people. Nothing between the published thresholds is estimated.

The dose calendar follows section 2 of each FDA label, with every step taken after 4 weeks. The side-effect chart divides the registry's head counts by the number who received at least one dose, 374 on Zepbound and 376 on Wegovy.

The cost calculator adds 18 four-week fills at the makers' self-pay prices for the dose the label schedule reaches in each fill, then divides the total by the average weight lost at week 72. With your own price it uses the same amount for every fill. All of these restate trial averages. None predicts an individual result, and none is medical advice.

Sources

  1. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
  2. ClinicalTrials.gov. SURMOUNT-5, NCT05822830, study results, first posted November 26, 2025. clinicaltrials.gov
  3. Eli Lilly and Company. Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial. Press release, May 11, 2025. investor.lilly.com
  4. American College of Cardiology. SURMOUNT-5: greater loss of weight, waist circumference with tirzepatide than semaglutide. Journal scan, July 10, 2025. acc.org
  5. Shukla AP, Dunn JP, Gomez Valderas E, et al. Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial. Diabetes Obes Metab 2026;28:452-462. doi:10.1111/dom.70215
  6. Galindo RJ, Aronne LJ, Horn DB, et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. J Endocrinol Invest 2026;49:1611-1620. doi:10.1007/s40618-026-02895-3
  7. Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med 2026;139:913-921. doi:10.1016/j.amjmed.2026.03.010
  8. le Roux CW, Done N, Brnabic AJM, et al. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. J Endocrinol Invest 2026;49:413-423. doi:10.1007/s40618-025-02792-1
  9. Mamas MA, Bays H, Li R, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open 2025;5:oeaf117. doi:10.1093/ehjopen/oeaf117
  10. le Roux CW, Busetto L, Aronne L, et al. A treat-to-target approach for obesity management: a post hoc analysis of the SURMOUNT-5 trial. Diabetes Obes Metab 2026;28:3355-3366. doi:10.1111/dom.70531
  11. Weill Cornell Medicine. Head-to-head trial compares weight loss drugs. May 2025. news.weill.cornell.edu
  12. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol 2025;13:949-963. PMID 40961952
  13. HCPLive. FDA approves higher dose semaglutide (Wegovy HD) injection 7.2 mg for obesity. March 19, 2026. hcplive.com
  14. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  15. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
  16. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
  17. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. doi:10.1056/NEJMoa2404881
  18. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025;392:2089-2099. PMID 40305708
  19. Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med 2025;392:427-437. doi:10.1056/NEJMoa2410027
  20. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med 2025;393:2409-2420. PMID 41406444
  21. ClinicalTrials.gov. SURMOUNT-MMO, NCT05556512. clinicaltrials.gov
  22. WEGOVY (semaglutide) prescribing information, NDA 215256/S-033. U.S. Food and Drug Administration, 2026. accessdata.fda.gov
  23. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-042. U.S. Food and Drug Administration, 2026. accessdata.fda.gov
  24. Novo Nordisk. Save on Wegovy: self-pay prices. Read November 19, 2026. wegovy.com
  25. Eli Lilly and Company. Zepbound coverage and savings: self-pay prices. Read November 19, 2026. zepbound.lilly.com
  26. Managed Healthcare Executive. FDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes. August 31, 2026. managedhealthcareexecutive.com
  27. Managed Healthcare Executive. CVS Caremark to put Zepbound back on formulary and add Foundayo. May 28, 2026. managedhealthcareexecutive.com
  28. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. cms.gov
  29. Healio. Continued obesity treatment linked to long-term weight loss. Report on Gasoyan H, et al., ObesityWeek, November 14, 2026. healio.com
  30. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564. doi:10.1111/dom.14725
  31. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
  32. Rodriguez PJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med 2024;184:1056-1064. doi:10.1001/jamainternmed.2024.2525

Keep your own doses and weigh-ins in one place.

Open Dose Insider